|
業務類別
|
-- |
|
業務概覽
|
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65. |
| 公司地址
| Kungsgatan 29, Stockholm, SWE, SE-111 56 |
| 電話號碼
| +46 86610026 |
| 傳真號碼
| +46 86616368 |
| 公司網頁
| https://www.diamyd.com |
| 員工數量
| 39 |
| Mr. Anna Styrud |
Chief Financial Officer |
-- |
14/11/2024 |
| Dr. Ulf Hannelius, PhD |
Chief Executive Officer |
-- |
14/11/2024 |
|
|
| Ms. Karin Rosen |
Director |
14/11/2024 |
| Ms. Maria-Teresa Essen-Moller |
Director |
14/11/2024 |
| Dr. Torbjorn Backstrom, PhD |
Independent Director |
14/11/2024 |
| Dr. Mark A. Atkinson, PhD |
Independent Director |
14/11/2024 |
| Dr. Karin M. Hehenberger, M.D.,PhD |
Independent Director |
14/11/2024 |
| Mr. Erik Nerpin |
Vice Chairman of the Board |
14/11/2024 |
| Mr. Anders Essen-Moller |
Chairperson of the Board |
14/11/2024 |
|
|
|
|
